Pacific Edge Limited, a global leader in cancer diagnostics, has published its Annual Report for the year ending 31 March 2025. The report highlights the company's resilient performance amid uncertainties surrounding Medicare coverage, showcasing improvements in sales force performance, operating efficiencies, and cash collection. These advancements position Pacific Edge for accelerated growth as it aims to regain Medicare coverage for its diagnostic tests. The company continues to develop and commercialize bladder cancer diagnostic and prognostic tests, maintaining its commitment to operational quality and compliance. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.